Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Non-Current Assets (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Other Non-Current Assets for 9 consecutive years, with $60000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 97.35% year-over-year to $60000.0, compared with a TTM value of $60000.0 through Dec 2025, down 97.35%, and an annual FY2025 reading of $60000.0, down 97.35% over the prior year.
  • Other Non-Current Assets was $60000.0 for Q4 2025 at VYNE Therapeutics, down from $241000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.5 million in Q4 2021 and bottomed at $54000.0 in Q3 2023.
  • Average Other Non-Current Assets over 5 years is $946500.0, with a median of $605000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets tumbled 98.09% in 2022, then soared 4605.56% in 2024.
  • Year by year, Other Non-Current Assets stood at $3.5 million in 2021, then crashed by 98.09% to $67000.0 in 2022, then soared by 49.25% to $100000.0 in 2023, then skyrocketed by 2162.0% to $2.3 million in 2024, then tumbled by 97.35% to $60000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for VYNE at $60000.0 in Q4 2025, $241000.0 in Q2 2025, and $1.3 million in Q1 2025.